Shingo Imanishi

514 total citations
31 papers, 371 citations indexed

About

Shingo Imanishi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Physiology. According to data from OpenAlex, Shingo Imanishi has authored 31 papers receiving a total of 371 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 5 papers in Physiology. Recurrent topics in Shingo Imanishi's work include Cancer Immunotherapy and Biomarkers (10 papers), Lung Cancer Treatments and Mutations (10 papers) and Lung Cancer Research Studies (8 papers). Shingo Imanishi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Lung Cancer Treatments and Mutations (10 papers) and Lung Cancer Research Studies (8 papers). Shingo Imanishi collaborates with scholars based in Japan and United States. Shingo Imanishi's co-authors include Ryuji Hayashi, Kazuyuki Tobe, Seisuke Okazawa, Minehiko Inomata, Kenta Kambara, Toshiro Miwa, Shoko Matsui, Yu Yamazaki, Masaharu Urakaze and Yûji Matsuya and has published in prestigious journals such as Scientific Reports, Journal of Allergy and Clinical Immunology and American Journal of Physiology-Endocrinology and Metabolism.

In The Last Decade

Shingo Imanishi

28 papers receiving 364 citations

Peers

Shingo Imanishi

ONCOL

PHYSI

PRM

EPIDE

Ken Desai United Kingdom

Daniel S. Gaul Switzerland

Fahmida Rasha United States

George Sotiropoulos Greece

Fengting Su China

Anne E. Wyman United States

Pixiong Su China

Francesca Bartoli‐Leonard United States

Hairong Yao China

Tingjie Wang China

Ken Desai United Kingdom

Shingo Imanishi

25 ×0.2

94 ×0.8

ONCOL

82 ×0.7

PHYSI

58 ×0.6

PRM

180 ×1.9

EPIDE

Citations per year, relative to Shingo Imanishi Shingo Imanishi (= 1×) peers Ken Desai

Countries citing papers authored by Shingo Imanishi

Since Specialization

Citations

This map shows the geographic impact of Shingo Imanishi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shingo Imanishi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shingo Imanishi more than expected).

Fields of papers citing papers by Shingo Imanishi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shingo Imanishi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shingo Imanishi. The network helps show where Shingo Imanishi may publish in the future.

Co-authorship network of co-authors of Shingo Imanishi

This figure shows the co-authorship network connecting the top 25 collaborators of Shingo Imanishi. A scholar is included among the top collaborators of Shingo Imanishi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shingo Imanishi. Shingo Imanishi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Inomata, Minehiko, Tomomi Ichikawa, Naoki Takata, et al.. (2025). Multicenter Retrospective Analysis of Pulmonary Sarcomatoid Carcinoma Clinically Diagnosed Using Small Biopsy Specimens. Cancer Diagnosis & Prognosis. 5(3). 363–369.

Inomata, Minehiko, Daisuke Furukawa, Naoki Takata, et al.. (2025). A Case of EGFR-mutant Squamous Cell Lung Cancer Treated With Necitumumab Combination Therapy. In Vivo. 39(2). 1207–1210. 1 indexed citations

Inomata, Minehiko, Naoki Takata, Seisuke Okazawa, et al.. (2024). Effectiveness of Chemoimmunotherapy in Small-cell Lung Cancer Patients With a Poor Performance Status or Higher Neutrophil/Lymphocyte Ratio. In Vivo. 39(1). 467–472. 1 indexed citations

Inomata, Minehiko, Naoki Takata, Seisuke Okazawa, et al.. (2024). Pure Red Cell Aplasia and Chromosomal Abnormality in a Patient With Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors: A Case Report. In Vivo. 38(3). 1509–1511. 1 indexed citations

Inomata, Minehiko, Naoki Takata, Seisuke Okazawa, et al.. (2024). Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expression. Molecular and Clinical Oncology. 20(6). 43–43.

Inomata, Minehiko, Naoki Takata, Seisuke Okazawa, et al.. (2023). Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer. Scientific Reports. 13(1). 10807–10807. 10 indexed citations

Inomata, Minehiko, Seisuke Okazawa, Kenta Kambara, et al.. (2022). Association of Tumor PD-L1 Expression With Time on Treatment Using EGFR-TKIs in Patients With EGFR-Mutant Non-small Cell Lung Cancer. Cancer Diagnosis & Prognosis. 2(3). 324–329. 7 indexed citations

Inomata, Minehiko, Naoki Takata, Seisuke Okazawa, et al.. (2021). Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 Expression. Cancer Diagnosis & Prognosis. 1(3). 173–177. 4 indexed citations

Inomata, Minehiko, Naoki Takata, Seisuke Okazawa, et al.. (2021). Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint Inhibitors. In Vivo. 35(3). 1687–1692. 5 indexed citations

10.

Takata, Naoki, Seisuke Okazawa, Kenta Kambara, et al.. (2020). Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer. Tumori Journal. 107(6). 536–541. 2 indexed citations

11.

Inomata, Minehiko, Naoki Takata, Seisuke Okazawa, et al.. (2020). Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy. Diagnostics. 10(12). 1006–1006. 13 indexed citations

12.

Inomata, Minehiko, Seisuke Okazawa, Shingo Imanishi, et al.. (2019). Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor. Anticancer Research. 39(12). 6887–6893. 26 indexed citations

13.

Inomata, Minehiko, Seisuke Okazawa, Kenta Kambara, et al.. (2018). Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy. Pathology & Oncology Research. 26(1). 327–333. 18 indexed citations

14.

Inomata, Minehiko, Hiroaki Tanaka, Seisuke Okazawa, et al.. (2017). Clinical Course After Initiation of Nivolumab Therapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer With or Without Pd-L1 Expression. Oncology and Therapy. 5(2). 181–185. 1 indexed citations

15.

Ichikawa, Tomomi, Ryuji Hayashi, Kensuke Suzuki, et al.. (2012). Sirtuin 1 activator SRT1720 suppresses inflammation in an ovalbumin‐induced mouse model of asthma. Respirology. 18(2). 332–339. 71 indexed citations

16.

Inomata, Minehiko, Ryuji Hayashi, Kenta Kambara, et al.. (2012). Miliary brain metastasis presenting with calcification in a patient with lung cancer: a case report. Journal of Medical Case Reports. 6(1). 16 indexed citations

17.

Inomata, Minehiko, Yukio Kawagishi, Kenta Kambara, et al.. (2011). Visceral adipose tissue level, as estimated by the bioimpedance analysis method, is associated with impaired lung function. Journal of Diabetes Investigation. 3(3). 331–336. 14 indexed citations

18.

Taniguchi, Hirokazu, et al.. (2008). [A case of chest pain variant asthma with headache].. PubMed. 46(3). 216–9. 1 indexed citations

19.

Taniguchi, Hirokazu, et al.. (2008). [Case of hepatopulmonary syndrome with no vascular dilation in chest CT].. PubMed. 46(6). 466–9. 1 indexed citations

20.

Taniguchi, Hirokazu, et al.. (2008). [A case of smoking-induced chest pain improved with beta2-stimulant].. PubMed. 46(7). 530–4. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact